Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ragaglitazar: The companies suspended clinical development of Ragaglitazar to regulate blood glucose and diabetic dyslipidemia after preclinical tests showed ra

Dr. Reddy Laboratories Ltd. (RDY), Hyderabad, India
Novo Nordisk A/S (NVO), Bagsvaerd, Denmark
Product: Ragaglitazar (DRF 2725 or

Read the full 193 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE